Ergoteles’s Precision BioSciences DTIL Stock Holding History

Ergoteles’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,587	Closed	-$92.4K	–	1381
2022 Q4	$92.4K	Buy	+2,587	New	+$102K	﹤0.01%	1236
2022 Q3	–	Sell	-8,150	Closed	-$391K	–	1649
2022 Q2	$391K	Buy	+8,150	New	+$478K	0.01%	968

Other funds holding DTIL

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's DTIL Position: Q1 2023 in Review

Ergoteles sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 2,587 shares — an estimated $92.4K sold.

Ergoteles first reported a position in DTIL in Q2 2022 and held it in 2 quarters. The position peaked at $391K in Q2 2022. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

Ergoteles reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 2,587 Precision BioSciences shares in Q1 2023, an estimated $92.4K.
Ergoteles first reported a position in Precision BioSciences in Q2 2022 and held it in 2 quarters.
Ergoteles's Precision BioSciences position peaked at $391K in Q2 2022.
86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.